MDT - Medtronic
$80.13 -2.04 (-2.48%)
Updated: 03:17 May 5, 2024 ESTNext Hour's AI Forecast
99.11%
Avg. Accuracy (AI)
$82.76
Next Session's AI Forecast
98.87%
Avg. Accuracy (AI)
$82.89
Next Week's AI Forecast
100%
Trend's Accuracy (AI)
$80.94
| Rank (0-100) |
| Rank (0-100) |
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 0.36 | -0.05 | -0.09 | 0.11 | -0.03 |
|---|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 0.36 | 0.91 | 0.84 | 0.85 | 0.88 |
|---|
STOCHASTIC METRIC
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
| Curr. Week | Next Week | Curr. Month | Curr. Quarter | 100% | 100% | 56.78% | 33.21% |
|---|
MOVING AVERAGE METRIC
| 5 Sessions | Change 5 Sessions | 20 Sessions | Change 20 Sessions | 50 Sessions | Change 50 Sessions | 200 Sessions | 81.83 | 1.41% | 80.69 | -2.06% | 82.39 | 0.72% | 81.8 |
|---|
RSI METRIC
| RS Hour | RSI Hour | RS Day | RSI Day | 0.64 | 69.23 | 5 | 39.02 |
|---|
Medtronic Technical Analysis News
News About Medtronic in last three days
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
The latest trading day saw Medtronic (MDT) settling at $81.76, representing a +0.09% change from its previous close.
At May 6, 2024, 9:50 pm
Zacks
Mentions in the news over the last three days
In the last three days Medtronic was mentioned 4 times in 1 different publications.
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
"Market participants will be closely following the financial results of Medtronic in its upcoming release. The company plans to announce its earnings on May 23, 2024. The company is expected to report EPS of $1.45, down 7.64% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $8.44 billion, indicating a 1.25% decline compared to the corresponding quarter of the prior year.", "The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.07% fall in the Zacks Consensus EPS estimate. At present, Medtronic boasts a Zacks Rank of #4 (Sell)."
At May 6, 2024, 9:50 pm
Zacks
Medtronic
20 On Hatch
Lower Hatch Street
Dublin 2
Ireland
353 1 438 1700
https://www.medtronic.com
| Sectors: | Healthcare |
| Industry: | Medical Devices |
| F. Time Employees: | 95000 |
Description
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Corporate Governance
Medtronic plc’s ISS Governance QualityScore as of May 1, 2024 is 6. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 6; Compensation: 3.
List of holders with stock participation in Medtronic.
| Holder Rank | Holder | Shares | Date Reported | % Out | Value |
|---|